Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Trust NASDAQ Cybersecurity ETF (CIBR) vs Johnson & Johnson (JNJ) Price & Performance

First Trust NASDAQ Cybersecurity ETFTrade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

First Trust NASDAQ Cybersecurity ETF vs Johnson & Johnson — how do they compare? First Trust NASDAQ Cybersecurity ETF trades at $95.49, while Johnson & Johnson trades at $249 (market cap $611.07B). The key difference: Johnson & Johnson pays a 2.11% dividend while First Trust NASDAQ Cybersecurity ETF pays none, and First Trust NASDAQ Cybersecurity ETF is trading nearer its 52-week high, Johnson & Johnson nearer its low. Which is the better fit depends on your goals.

CIBRJNJ
52-Week High
$94.73$267.24
52-Week Low
$60.74$155.17
Market Cap
$611.07B
Volume
6,156,228
Sector
Health
Enterprise Value
$644.01B
Dividend Yield
2.11%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Trust NASDAQ Cybersecurity ETF

CIBR trades at $91.84, down 0.04% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The ETF has demonstrated strong performance, outperforming the S&P 500 by a three-to-one margin year-to-date, driven by robust cybersecurity spending trends. A dividend of $0.07 is scheduled for June 30, 2026. Recent news highlights institutional accumulation and positive momentum in the cybersecurity sector.

The outlook for CIBR is supported by growing global cybersecurity expenditures, projected to exceed $300 billion in 2026, and AI-driven demand. Risks include sector volatility and concentrated tech exposure. Analyst sentiment is positive, with recent upgrades citing reasonable valuation and secular growth, though investors should weigh high institutional interest against market cyclicality.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $257.77, up 0.31% with a bullish technical signal and strong institutional support. The stock shows robust fundamentals with 2025 revenue of $94.19B, net income margin of 21.83%, and consistent earnings beats. Recent dividend declaration of $1.34 and positive analyst coverage with 52.5% buy ratings reinforce confidence. The current price sits near pivot point resistance at $258, with technical indicators showing bullish momentum from moving averages.

JNJ presents a compelling long-term investment with stable cash flows, strong profitability metrics, and defensive healthcare positioning. Upside potential exists toward the $281 consensus price target, though risks include rising debt-to-asset ratio (24.06% in 2025) and patent expiration headwinds. The stock's 60+ year dividend growth history provides income stability amid market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About First Trust NASDAQ Cybersecurity ETF

The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.

Read more on CIBR

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ